Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures

Rhea-AI Summary

Medtronic (NYSE: MDT) announced FDA clearance of the Hugo™ robotic-assisted surgery (RAS) system for use in minimally invasive urologic procedures including prostatectomy, nephrectomy, and cystectomy.

The release notes the Expand URO IDE study—described as the largest US multi-port robotic urology trial—met primary safety and effectiveness endpoints, and estimates those urologic procedures total about 230,000 surgeries per year in the U.S. Medtronic plans a purposeful U.S. launch with broader specialty indications expected later.

Positive

• FDA clearance for Hugo RAS in urologic procedures (Dec 3, 2025)
• Expand URO study met primary safety and effectiveness endpoints
• 230,000 U.S. urologic surgeries per year covered by indications
• Established use in tens of thousands of procedures across >30 countries

Negative

• Initial U.S. clearance limited to urologic procedures only
• Rollout described as a purposeful launch, implying phased availability

News Market Reaction – MDT

+0.02%

+0.02% Session close to close

In the Dec 4 session, MDT gained 0.02%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds a significant U.S. regulatory milestone, with Hugo RAS cleared for minimally ...

Analysis

This announcement adds a significant U.S. regulatory milestone, with Hugo RAS cleared for minimally invasive urologic procedures that account for about 230,000 surgeries annually. It builds on prior FDA approvals and Medtronic’s broader surgical ecosystem, including digital tools and training. Investors may track future indications, adoption across more than 30 countries and 5 continents, and how this platform complements the company’s existing growth drivers and recent earnings momentum.

Key Figures

Annual U.S. urologic procedures: 230,000 surgeries per year Countries using Hugo RAS: more than 30 countries Continents with Hugo use: 5 continents

3 metrics

Annual U.S. urologic procedures 230,000 surgeries per year Prostatectomy, nephrectomy, cystectomy procedures addressable by Hugo RAS

Countries using Hugo RAS more than 30 countries Hugo RAS usage outside the U.S.

Continents with Hugo use 5 continents Geographic breadth of Hugo RAS procedures outside U.S.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 04	Dividend declaration	Positive	-0.6%	Announced $0.71 Q3 FY26 cash dividend and extended dividend streak.
Dec 03	FDA clearance	Positive	+0.0%	FDA cleared Hugo RAS for minimally invasive urologic procedures.
Dec 02	Product launch	Positive	-1.3%	Began U.S. commercial launch of MiniMed 780G with Instinct sensor.
Nov 18	Earnings results	Positive	+4.7%	Reported Q2 FY26 growth, EPS of $1.07 GAAP and $1.36 non-GAAP.
Nov 05	Earnings notice	Neutral	-0.4%	Announced timing and format for upcoming Q2 FY26 results release.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings beats have seen stronger positive reactions, while product/FDA and dividend news have shown muted or mixed price responses.

Recent Company History

Over recent months, Medtronic reported strong Q2 FY26 results with revenue of $8.96B and raised guidance, which coincided with a 4.69% gain. Product and regulatory milestones, including the MiniMed 780G U.S. launch and prior FDA clearances, produced mild or negative moves, suggesting limited immediate pricing of device approvals. The latest dividend declaration of $0.71 per share also saw a small negative reaction. Today’s Hugo RAS FDA clearance continues a stream of innovation-focused updates within this backdrop.

Key Terms

robotic-assisted surgery, urologic, minimally invasive, investigational device exemption, +1 more

5 terms

robotic-assisted surgery medical

"Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures."

Robotic-assisted surgery uses a surgeon-controlled robotic system to perform or assist with operations, where the doctor operates instruments through small incisions while a machine translates their movements into precise actions. For investors, it matters because these systems change procedure costs, hospital purchasing and training needs, and recurring revenue from instruments and service contracts—similar to how a new industrial robot can reshape manufacturing costs and output.

urologic medical

"FDA has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures."

Urologic describes anything related to urology, the medical specialty that treats the urinary system (kidneys, bladder, ureters, urethra) and the male reproductive organs. For investors, urologic products, procedures, or clinical results signal potential markets for drugs, devices, or diagnostics — like plumbing and hardware for the body's waste and reproductive systems — where regulatory approvals, insurance coverage, and patient demand drive revenue and risk.

minimally invasive medical

"indicated for use in minimally invasive urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy"

Medical procedures described as minimally invasive use small cuts, flexible tubes or tiny cameras to treat or diagnose problems with far less cutting than traditional surgery — like using a keyhole instead of tearing down a wall. Investors care because these approaches can shorten hospital stays, lower complication rates and change equipment and reimbursement needs, which can speed adoption and reshape market demand for devices, supplies and services.

investigational device exemption regulatory

"The Expand URO investigational device exemption clinical study — the largest ever completed"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.

digital ecosystem technical

"The Hugo RAS system connects seamlessly with the Touch Surgery™ ecosystem, which provides pre-operative training tools"

A digital ecosystem is a network of interconnected online tools, services, and platforms that work together to provide a seamless experience for users. It’s like a digital neighborhood where different services—such as shopping, communication, and entertainment—are linked, making it easier to access multiple functions in one place. For investors, understanding a digital ecosystem helps identify how a company’s digital presence can drive growth and create competitive advantages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Hugo RAS system brings choice to the U.S., coupled with the full suite of Medtronic surgical offerings, ultimately creating a connected and integrated operating room today and into the future.

GALWAY, Ireland, Dec. 3, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in surgical innovation, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures. The Hugo RAS system's clearance brings a versatile robotic-assisted platform to U.S. surgeons and health systems seeking to expand soft-tissue robotic surgery programs and access to minimally invasive care.

The U.S. leads the world in robotic surgery adoption, yet hospitals continue to face challenges in capacity and access. The introduction of the Hugo RAS system in the U.S. helps address this gap, offering an innovative approach to robotic-assisted surgery from the global leader in surgery and bringing choice to hospitals and surgeons across the country.

"This is an incredibly exciting day for healthcare in the United States. FDA clearance of the Hugo RAS system means there is now choice for hospitals looking to expand their robotic programs and increases access for patients," said Rajit Kamal, vice president and general manager of Robotic Surgical Technologies within the Surgical business of Medtronic. "As we begin our purposeful launch of the Hugo RAS system in the U.S., our focus is on building a strong foundation with leading hospitals through our differentiated approach to partnership, rooted in our enduring commitment to provide an excellent customer experience and enable surgical teams to deliver the best possible outcomes for their patients."

Thoughtfully designed with input from surgeons and hospital administrators to shape the future of surgery, the Hugo RAS system includes three main differentiators:

• Modular Design: The Hugo RAS system's innovative modular design means the robotic arms can be easily moved, shared, and deployed across any care setting — helping to maximize utilization and providing surgeons flexibility to customize their approach to optimize anatomical access for each patient's unique needs. The open design of the surgeon console provides greater situational awareness and visualization, reduces physical strain, and creates enhanced training opportunities for surgical teams — enabling better bedside communication and team integration.
   
• Digital Ecosystem: The Hugo RAS system connects seamlessly with the Touch Surgery™ ecosystem, which provides pre-operative training tools, remote tele-proctoring capabilities, and AI-powered post-operative case insights.^† Surgeons may securely access case videos minutes after a procedure is completed, supporting continuous improvement and collaboration among hospital teams and with their peers in the global surgical community.
   
• Differentiated Partnership: Medtronic is the first and only company that can meet surgeon needs across all surgical modalities — open, laparoscopic, and robotic-assisted. The addition of the Hugo RAS system provides surgical teams access to world-class robotic training, deep clinical and technical expertise, and choice when determining the best surgical approach for each patient's unique needs, with the opportunity to use trusted Medtronic technologies and instruments as technology advances. 

"The Hugo RAS system represents a new and exciting approach to robotic-assisted surgery," said Dr. James Porter, a urologic surgeon and chief medical officer for Robotic Surgical Technologies and Digital Technologies within the Surgical business at Medtronic. "We're excited for surgical teams in the U.S. to experience the differentiated technology and partnership from Medtronic, which supports them at every stage of their robotic surgical journey."

With FDA clearance, the Hugo RAS system is indicated for use in minimally invasive urologic surgical procedures including prostatectomy, nephrectomy, and cystectomy — common procedures that account for about 230,000 surgeries per year in the U.S.

The Expand URO investigational device exemption clinical study — the largest ever completed for multi-port robotic-assisted urological surgery in the U.S. — demonstrated that the Hugo RAS system met primary safety and effectiveness endpoints in urologic surgical procedures, with outcomes that are consistent with published literature.

Outside the U.S., the Hugo RAS system has been used in tens of thousands of urologic, gynecologic, and general surgery procedures in more than 30 countries across 5 continents. Medtronic intends to expand the Hugo RAS system's use in the U.S. to additional surgical specialties over time, with indications for general and gynecologic surgical procedures expected to follow the initial urology clearance.

The introduction of the Hugo RAS system in the U.S. builds on Medtronic's broad surgical offering, including the Touch Surgery ecosystem, to deliver a connected, integrated operating room — today and in the future.

For more information, visit medtronic.com/hugoishere.

†The Medtronic Touch Surgery™ ecosystem is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition. Performance Insights are available for select procedures, instruments, and anatomy.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777

Ryan Weispfenning
Investor Relations
+1-612-839-4549

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-hugo-robotic-assisted-surgery-system-for-urologic-surgical-procedures-302632328.html

SOURCE Medtronic plc

FAQ

What did Medtronic (MDT) announce on Dec 3, 2025 about the Hugo RAS system?

Medtronic announced FDA clearance of the Hugo RAS system for minimally invasive urologic procedures.

Which urologic procedures is the Hugo RAS system cleared for in the U.S. (MDT)?

The Hugo RAS system is indicated for prostatectomy, nephrectomy, and cystectomy in the U.S.

How many U.S. urologic surgeries annually are covered by Hugo RAS indications?

The announcement states those procedures account for about 230,000 surgeries per year in the U.S.

Did clinical data support the Hugo RAS FDA clearance for MDT?

Yes—the Expand URO IDE study, described as the largest U.S. multi-port robotic urology trial, met its primary safety and effectiveness endpoints.

Will Hugo RAS be available for other specialties in the U.S. for MDT?

Medtronic expects general and gynecologic surgical indications to follow the initial urology clearance over time.

How widely has Hugo RAS been used outside the U.S. according to Medtronic (MDT)?

Medtronic says the Hugo RAS system has been used in tens of thousands of procedures across more than 30 countries on five continents.